Azerbaijani
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Orthostatic Intolerance After Bariatric Surgery

Yalnız qeydiyyatdan keçmiş istifadəçilər məqalələri tərcümə edə bilərlər
Giriş / Qeydiyyatdan keçin
Bağlantı panoya saxlanılır
StatusAktiv, işə qəbul deyil
Sponsorlar
Vanderbilt University Medical Center

Açar sözlər

Mücərrəd

More than 78 million adults in the U.S. are obese. Bariatric surgery is the only modality that results in sustained weight loss along with reversal of diabetes mellitus, and a decrease in cardiovascular events. Obesity is associated with increased sympathetic nervous system (SNS) activity that contributes to blood pressure regulation; sympathetic vasoconstrictor activity is maximally activated upon standing and is fundamental for the maintenance of orthostatic tolerance. After bariatric surgery, there is a significant and sustained reduction in SNS activity at three and six months after the procedure, which is related to weight loss. Recently, multiple retrospective studies have reported an orthostatic intolerance (OI) syndrome after bariatric surgery characterized by chronic pre-syncopal symptoms, syncope and orthostatic hypotension. In the Vanderbilt University Medical Center bariatric surgical center, 741 post-bariatric surgery patients reported OI symptoms, 98 (13.2%) of these patients, progressed to chronic OI and in17 cases, the OI was so disabling that patients initiated treatment with pressor agents. More than 50% of OI cases in the cohort developed the condition during a weight-stable period. Hence, investigators propose the novel hypothesis that after bariatric surgery, the persistent reduction in SNS activity contributes to impaired orthostatic tolerance, which is independent of weight loss.
Furthermore, considering that SNS vasoconstrictor activity depends on synaptic norepinephrine concentrations, investigators propose a proof-of-concept study to test the hypothesis that the norepinephrine transporter (NET) inhibitor, atomoxetine, which increases synaptic norepinephrine concentrations, will improve post-bariatric OI. Understanding the changes in SNS activity and its contribution to orthostatic tolerance after bariatric surgery is of utmost importance to unravel the mechanisms of a novel and unrecognized syndrome, post-bariatric OI. In 2014, nearly 200,000 individuals in the US underwent bariatric surgery, and the number of bariatric surgery procedures is expected to increase by 22% each year. It is projected, therefore, an increase in the incidence of post-bariatric OI.
Participants with Roux-en-Y gastric bypass (RYGB) and Vertical sleeve gastrectomy (VSG) will be studied.
OI is a chronic and disabling condition; treatment is challenging because current therapies have debatable efficacy.
The proposed application will not only provide central knowledge on the pathophysiology of this new syndrome but also will fill an unmet therapeutic need by repurposing NET inhibitors for the treatment of OI.

Tarixlər

Son Doğrulandı: 03/31/2020
İlk təqdim: 01/15/2019
Təxmini qeydiyyat təqdim edildi: 01/15/2019
İlk Göndərmə: 01/17/2019
Son Yeniləmə Göndərildi: 04/07/2020
Son Yeniləmə Göndərildi: 04/08/2020
Həqiqi Təhsilin Başlama Tarixi: 06/30/2018
Təxmini İlkin Tamamlanma Tarixi: 11/30/2020
Təxmini İşin Tamamlanma Tarixi: 11/30/2020

Vəziyyət və ya xəstəlik

Orthostatic Intolerance

Müdaxilə / müalicə

Drug: Atomoxetine

Drug: Placebo

Faza

Faza 1

Qol Qrupları

QolMüdaxilə / müalicə
Experimental: Roux-en-Y gastric bypass (RYGB)/Atomoxetine
Participants with standard of care RYGB will receive atomoxetine, 0.5 mg/kg/day for 3 days
Experimental: Vertical sleeve gastrectomy (VSG) /Atomoxetine
Participants with standard of care VSG will receive atomoxetine 0.5 mg/kg/day for 3 days
Placebo Comparator: Roux-en-Y gastric bypass (RYGB)/Placebo
Participants with standard of care RYGB will receive placebo 0.5 mg/kg/day for 3 days
Placebo Comparator: Vertical sleeve gastrectomy (VSG)/ Placebo
Participants with standard of care VSG will receive placebo 0.5 mg/kg/day for 3 days

Uyğunluq Kriteriyaları

Təhsil üçün uyğun yaşlar 18 Years Üçün 18 Years
Təhsilə Uyğun CinslərAll
Sağlam Könüllüləri qəbul edirBəli
Kriteriyalar

Inclusion Criteria:

- Obese subjects that will undergo bariatric surgery or medical weight loss.

- Age 18-60 years

- BMI >35 kg/m2

- Weight < 400 lbs

Exclusion Criteria:

- Diabetes type 1

- Use of an alpha blockers, clonidine, beta-blockers.

- Pregnancy or breast-feeding. Women of childbearing potential will be required to have undergone tubal ligation or to be using an oral contraceptive or barrier methods of birth control.

- The use of any strong CYP2D6 inhibitor (e.g., fluoxetine, paroxetine, quinidine, tipranavir).

- Use of selective NET inhibitors.

- Use of monoamine oxidase inhibitors.

- Cardiovascular disease such as myocardial infarction within six months prior to the study, presence of angina pectoris, significant arrhythmia, congestive heart failure (left ventricular hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis or hypertrophic cardiomyopathy

- History of serious neurologic disease such as cerebral hemorrhage, stroke, or transient ischemic attack

- Hematocrit < 34%

- Any underlying or acute disease requiring regular medication which could possibly pose a threat to the subject or make implementation of the protocol or interpretation of the study results difficult

- Mental conditions rendering a subject unable to understand the nature, scope and possible consequences of the study

- Inability to comply with the protocol, e.g., uncooperative attitude, inability to return for follow-up visits, unlikelihood of completing the study, and investigator discretion

Nəticə

İlkin nəticə tədbirləri

1. Orthostatic Tolerance [about 1 hour]

the time between the start of the 60 degree head up tilt until pre-syncope Participant will be placed in 60degree head-up tilt (HUT) for 30 min following by lower body negative pressure in escalating negative pressures (-20, -40, -60 mm Hg) until pre-syncope (defined as systolic BP (SBP, mm Hg) <80 or SBP>90 and pre-syncopal symptoms (nausea, lightheadedness, dizziness)

İkincili Nəticə Tədbirləri

1. Norepinephrine transporter Inhibition [baseline and 30 minutes]

the ratio of dihydroxyphenylglycol (DHPG) to Norepinephrine is used as the biomarker for NET inhibition

Facebook səhifəmizə qoşulun

Elm tərəfindən dəstəklənən ən tam dərman bitkiləri bazası

  • 55 dildə işləyir
  • Elm tərəfindən dəstəklənən bitki mənşəli müalicələr
  • Təsvirə görə otların tanınması
  • İnteraktiv GPS xəritəsi - yerdəki otları etiketləyin (tezliklə)
  • Axtarışınızla əlaqəli elmi nəşrləri oxuyun
  • Təsirlərinə görə dərman bitkilərini axtarın
  • Maraqlarınızı təşkil edin və xəbər araşdırmaları, klinik sınaqlar və patentlər barədə məlumatlı olun

Bir simptom və ya bir xəstəlik yazın və kömək edə biləcək otlar haqqında oxuyun, bir ot yazın və istifadə olunan xəstəliklərə və simptomlara baxın.
* Bütün məlumatlar dərc olunmuş elmi araşdırmalara əsaslanır

Google Play badgeApp Store badge